Cellbion
Financials
Valuation Metrics
Cellbion's Market Cap is ₩1728B. At end of 2025 it was ₩3046B. Ranked #935 of 2,421 in KR market (top 39%), #451 of 1,640 on KOSDAQ (top 28%), #104 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 172.80B KRW | KR#935/2,421 Sec#104/231 |
| Revenue | 2.15B KRW | KR#2,381/2,421 Sec#214/231 |
| Net Income | 7.75B KRW | KR#1,051/2,421 Sec#66/231 |
| Total Assets | 83.32B KRW | KR#1,910/2,421 Sec#155/231 |
| Net Assets | 36.13B KRW | KR#2,111/2,421 Sec#185/231 |
| Employees | 43 | KR#2,109/2,421 Sec#193/231 |
| Value | ||
| P/E | 22.30x | KR#1,216/2,421 Sec#71/231 |
| P/B | 4.78x | KR#2,235/2,421 Sec#189/231 |
| P/S | 80.54x | KR#2,387/2,421 Sec#206/231 |
| FCF Yield | -4.06% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 21.45% | KR#152/2,421 Sec#12/231 |
| ROA | 9.30% | KR#322/2,421 Sec#25/231 |
| Op. Margin | -447.16% | KR#2,364/2,421 Sec#204/231 |
| Revenue Growth | -15.05% | KR#2,039/2,421 Sec#186/231 |
| Financial Health | ||
| Debt Ratio | 130.61% | KR#1,795/2,421 Sec#200/231 |
| Total Debt | 7.05B KRW | KR#1,720/2,421 Sec#158/231 |
| FCF | -7.02B KRW | KR#1,592/2,421 Sec#130/231 |
| Cash | 1.71B KRW | KR#2,269/2,421 Sec#214/231 |
| Current Ratio | 33.44x | KR#7/2,421 Sec#3/231 |
| Performance | ||
| 1Y Return | -28.59% | KR#1,520/2,421 Sec#119/231 |
| 1M Return | 2.14% | KR#1,017/2,421 Sec#75/231 |
| From 52W High | -68.27% | KR#2,150/2,421 Sec#182/231 |
| 1Y MDD | -73.67% | KR#2,132/2,421 Sec#188/231 |
| Trading | ||
| Volume | 13,301 shares | KR#1,791/2,421 Sec#179/231 |
| Trading Value | 177.4M KRW | KR#1,318/2,421 Sec#132/231 |
| Foreign Own. | 3.39% | KR#1,180/2,421 Sec#108/231 |
| Per Share | ||
| EPS | 601 KRW | KR#925/2,421 Sec#64/231 |
| BPS | 2,800 KRW | KR#1,900/2,421 Sec#145/231 |
Company Info
CellBion was established in 2010 with the aim of becoming a global leader in radiopharmaceuticals, and was listed on the KOSDAQ market in 2024. The company focuses on developing new anti-cancer drugs for precision medicine and targeted therapy, with Lu-177-DGUL currently under development. It produces generic specialty pharmaceuticals and operates a contract development and manufacturing organization (CDMO) business through its GMP-certified injectable vial manufacturing facility. CellBion delivers patient-specific precision anti-cancer therapy for PSMA protein-expressing prostate cancer, improving patient quality of life and advancing medical care. CellBion is headquartered in Jongno-gu, Seoul.